Alpha 2.0
Login Register
» Authors » Adrian Palfreeman

Adrian Palfreeman

Explore the profile of Adrian Palfreeman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 1585
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Public Health
Top 10 Co-Authors
Martin Fisher
Chloe Orkin
Clifford Leen
Mark Nelson
Margaret Johnson
Frank Post
Robert C Read
Mehmood Mughal
Sunil Sharma
Martin J Llewelyn
Published In
HIV Med
AIDS
J Acquir Immune Defic Syndr
J Infect
Sex Transm Infect
Affiliations
Soon will be listed here.
Recent Articles
1.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
Liu X, Munro A, Wright A, Feng S, Janani L, Aley P, et al.
J Infect . 2023 Apr; 87(1):18-26. PMID: 37085049
Background: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were...
2.
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect . 2023 Apr; 86(5):540-541. PMID: 37055303
No abstract available.
3.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2,...
Munro A, Feng S, Janani L, Cornelius V, Aley P, Babbage G, et al.
Lancet Infect Dis . 2022 May; 22(8):1131-1141. PMID: 35550261
Background: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the...
4.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect . 2022 Apr; 84(6):795-813. PMID: 35405168
Objectives: To evaluate the persistence of immunogenicity three months after third dose boosters. Methods: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a...
5.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D, et al.
Lancet . 2021 Dec; 398(10318):2258-2276. PMID: 34863358
Background: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we...
6.
Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study)
Lee M, Snell L, Douthwaite S, Fidler S, Fitzgerald N, Goodwin L, et al.
HIV Med . 2021 Sep; 23(2):121-133. PMID: 34555242
Background: The contribution of HIV to COVID-19 outcomes in hospitalized inpatients remains unclear. We conducted a multi-centre, retrospective matched cohort study of SARS-CoV-2 PCR-positive hospital inpatients analysed by HIV status....
7.
British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020
Palfreeman A, Sullivan A, Rayment M, Waters L, Buckley A, Burns F, et al.
HIV Med . 2020 Dec; 21 Suppl 6:1-26. PMID: 33333625
No abstract available.
8.
Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial
Ghazi L, Baker J, Sharma S, Jain M, Palfreeman A, Necsoi C, et al.
Am J Hypertens . 2019 Dec; 33(1):43-52. PMID: 31800000
Background: The association between hypertension (HTN) and inflammatory biomarkers (interleukin-6 [IL-6] and high-sensitivity C-reactive protein [hsCRP]) in HIV-positive persons with CD4+ count >500 cells/mm3 is unknown. Methods: We studied HTN...
9.
ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial
Sereti I, Gulick R, Krishnan S, Migueles S, Palfreeman A, Touzeau-Romer V, et al.
J Acquir Immune Defic Syndr . 2019 Jun; 81(4):456-462. PMID: 31241541
Background: The benefit of immediate antiretroviral therapy (ART) at CD4 >500 cells/μL was established in the Strategic Timing of Antiretroviral Treatment (START) study. The benefits and risks of immediate ART...
10.
BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018
Brady M, Rodger A, Asboe D, Cambiano V, Clutterbuck D, Desai M, et al.
HIV Med . 2019 Mar; 20 Suppl 2:s2-s80. PMID: 30869189
No abstract available.